KANSAS CITY, Mo., Aug. 2, 2018 /PRNewswire/ -- Novation Companies, Inc. (OTC: NOVC) ("Novation" or the "Company"), whichthrough its subsidiary Healthcare Staffing, Inc. provides outsourced health care staffing and related services in the State of Georgia, announced that its 2018 Annual Meeting of Shareholders (the "2018 Annual Meeting")
Shareholder proposals intended to be presented at the 2018 Annual Meeting pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended, must be received by the Company not later than 5:00 p.m. Eastern Daylight Time on August 13, 2018, in order to be considered for inclusion in the Company's proxy statement for the 2018 Annual Meeting. For a shareholder to bring business before the 2018 Annual Meeting outside of Rule 14a-8 or to nominate a director, it must provide timely written notice to the Company in accordance with the advance notice provisions of the Company's Second Amended and Restated Bylaws.
About Novation Companies, Inc.
Novation Companies, Inc. and its subsidiaries, through its wholly-owned subsidiary Healthcare Staffing, Inc., provides outsourced health care staffing and related services in the State of Georgia. Novation also owns a portfolio of mortgage securities which generate earnings to support on-going financial obligations. Novation's common stock, par value $0.01 per share, is traded on the OTC Pink marketplace of the OTC Markets Group, Inc. under the symbol "NOVC".
For more information, please visit www.novationcompanies.com or contact Carolyn Campbell, Chief Financial Officer, at 816.237.7000 or firstname.lastname@example.org.
View original content:http://www.prnewswire.com/news-releases/novation-companies-announces-date-of-2018-annual-meeting-of-shareholders-300691317.html
SOURCE Novation Companies, Inc.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All